For shareholder queries, please email Questions@valirx.com. You will receive an acknowledgement of your question, and a commitment to address your question in the periodic answers sessions. Valirx commits to answering questions in a clear, concise and factual manner. Where a question cannot be answered due to regulatory or commercial sensitivity reasons, the question will still be reported, with the reason for no answer being provided.
Answer Sessions: June-2020-Answers.pdf
Answer Sessions: July 2020 Answers.pdf
Answer Sessions: Pre-AGM July 2020 Answers.pdf
Answer Sessions: Late July 2020 Answers.pdf
Answer Sessions: August 2020 Answers.pdf